Utility of the FTLD-CDR in the mild FTLD: Data from the ARTFL/LEFFTDS Consortium

Disclosure:
Dr. Miyagawa has nothing to disclose.

MS Clinical Assessments and Outcome Measures

Start Time

Pub.

Title

Presenter

11:30 AM

001

Predictors of Processing Speed Test Performance in a Large Multiple Sclerosis Population

Disclosure:
Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals.

Disclosure:
Dr. Flamini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai and Lundbeck. Dr. Flamini has received research support from GW.

Disclosure:
Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Eli Lilly and Promius/Dr Reddy's Labs. Dr. Reed has received research support from Allergan, Promius/Dr. Reddy's Labs.

Frontotemporal Dementia I

Start Time

Pub.

Title

Presenter

11:30 AM

003

Neuropsychiatric Symptoms and the Ultimate Game in Frontotemporal Dementia Compared to Alzheimer's Disease

Disclosure:
Dr. Yerokhin has nothing to disclose.

MS Clinical Assessments and Outcome Measures

Start Time

Pub.

Title

Presenter

11:30 AM

003

myMS; A Comprehensive Patient-Centered Mobile App to Monitor MS at Home

Disclosure:
Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.

The Use and Yield of Vascular Imaging in Patients with Deep Intracerebral Hemorrhage

Disclosure:
Dr. Moretti has nothing to disclose.

Atypical Parkinsonism

Start Time

Pub.

Title

Presenter

11:30 AM

004

Impact of Supine Hypertension in Target Organ Damage and Mortality in Patients with Neurodegenerative Synucleinopathies

Disclosure:
Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and Biogen. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session

Start Time

Pub.

Title

Presenter

11:30 AM

004

Cognitive Abnormalities In DM1: A Five Years Longitudinal Study

Disclosure:
Dr. Angelini has nothing to disclose.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

004

The Italian chROnic migraiNe (IRON) Registry: a report from the first 340 patients

Disclosure:
Dr. Barbanti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with electroCore, LLC, Eli Lilly, Lusofarmaco, MSD, Novartis, Teva, and Visupharma.

Frontotemporal Dementia I

Start Time

Pub.

Title

Presenter

11:30 AM

004

Getting Granular with Progranulin: Abnormal Eating in FTLD+GRN

Disclosure:
Dr. McCollum has nothing to disclose.

MS Clinical Assessments and Outcome Measures

Start Time

Pub.

Title

Presenter

11:30 AM

004

Automated gait analysis using wearable sensors can detect objective and reliable quantification of disability in people with Multiple Sclerosis

Identifying SPMS: Are U.S. Neurologists Aligned on the Most Influential Disease and Patient Metrics?

Disclosure:
Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Dr. Naismith has received personal compensation in an editorial capacity as the Associate Editor NEJM Journal Watch. Dr. Naismith has received research support from Acorda, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, and Novartis.

Perampanel Use in Established, Refractory, and Super-Refractory Status Epilepticus (SE): a Summary of Cases from Austria, Finland, Germany, and Spain

Disclosure:
Dr. Strzelczyk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Desitin, UCB Pharma, Zogenix. Dr. Strzelczyk has received research support from UCB Pharma, Zogenix.

Electrodiagnostic elucidation of a novel variant in the acetylcholine receptor gene identified by rapid trio exome sequencing, leading to the diagnosis and treatment of congenital myasthenia syndrome in an infant presenting with fetal akinesia deformation sequence.

Disclosure:
Dr. Schwarz has nothing to disclose.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

006

Provider Preference for Acute Migraine Treatment in the Emergency Room: A Professional Practice Gap

Effect of Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Safety and Efficacy of Adjunctive Perampanel in Patients Aged 4 to ?12 years with Partial-Onset Seizures (POS): Final Results from the 311 Core Study

Disclosure:
Dr. Milh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Shire, Novartis, Livanova and GW Pharma.

The Power of Case Reporting in Neuro-Oncology II

Start Time

Pub.

Title

Presenter

11:30 AM

007

Multinodular and Vacuolating Neuronal Tumor - Are We Only Seeing the Tip of the Iceberg?

A Clinical Staging System and Convenient Prognostic Tool for Progressive Supranuclear Palsy

Disclosure:
Dr. Golbe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS, AbbVie, and USB. Dr. Golbe has received royalty, license fees, or contractual rights payments from Rutgers University.

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session

Start Time

Pub.

Title

Presenter

11:30 AM

009

EMG, MEP, and SSEP in the Intraoperative Neurophysiologic Monitoring of Lumbar Surgeries

Disclosure:
Dr. Nguyen has nothing to disclose.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

009

Cognitive Dysfunction in Chronic Migraine

Disclosure:
Dr. Butt has nothing to disclose.

Frontotemporal Dementia I

Start Time

Pub.

Title

Presenter

11:30 AM

009

Frontotemporal Lobar Degeneration in the Differential Diagnosis of the Oldest-Old

Disclosure:
Dr. Embree has nothing to disclose.

MS Clinical Assessments and Outcome Measures

Start Time

Pub.

Title

Presenter

11:30 AM

009

LIFEware Life Satisfaction and Pessimism are Correlated with the Beck Depression Inventory-Fast Screen and with Disability Progression in Individuals with Multiple Sclerosis

Disclosure:
Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, EMD Serono, Genentech, Novartis, Mallinckrodt, and Celgene. Dr. Weinstock-Guttman has received research support from Biogen Idec, Novartis, and Genentech.

Disclosure:
Dr. Hogan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Chemical. Dr. Hogan has received research support from UCB Pharmaceuticals, Neurelis Pharnaceuticals, Biogen Inc.

High Prevalence of Rape and Sexual Abuse among Chronic and Refractory Migraine Patients

Disclosure:
Dr. Oterino Duran has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Almirall, Merck Serono, TEVA, Sanofi Genzyme, Allergan, MSD and Novartis. Dr. Oterino Duran has received research support from Sanofi Genzyme, Novartis.

Screening for Cognitive Impairment in People with Multiple Sclerosis: Is A Unidimensional Measure Really Sufficient to Detect the Cognitive Elephant in the Room?

Disclosure:
Dr. Gudesblatt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Novartis, Sanofi-Genzyme, and Teva Neuroscience. Dr. Gudesblatt has received research support from Acorda, Adamas, Biogen, Novartis, Roche, Sanofi-Genzyme, and Teva Neuroscience.

A Mixed Picture: Dermatomyositis with features of Necrotizing Myopathy

Disclosure:
Dr. Ullah has nothing to disclose.

Epilepsy: Antiseizure Medications II

Start Time

Pub.

Title

Presenter

11:30 AM

010

Analysis of Hematological and Serum Chemistry Abnormalities in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures

Disclosure:
Dr. Kotagal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with LivaNova, UCB Pharma, Eisai and Greenwich Biosciences.

The Power of Case Reporting in Neuro-Oncology II

Start Time

Pub.

Title

Presenter

11:30 AM

010

A case of Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR): a distinct genetic locus with an excellent outcome

Disclosure:
Dr. Nemade has nothing to disclose.

Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support

Start Time

Pub.

Title

Presenter

11:30 AM

010

Early Prediction of Malignant Brain Edema After Ischemic Stroke: a Systematic Review and Meta-Analysis

Disclosure:
Dr. Parnes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory committee or as a consultant for the Kadmon Corporation and Teva Neuroscience. Payment for contributions to Medlink.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

014

Serum Phosphate Levels in Patients with Migraine

Disclosure:
Dr. Jung has nothing to disclose.

Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I

Cerebral Small Vessel Disease and Cervicocerebral Large Artery Stenosis Independently Increase Ischemic Stroke Risk in the General Population

Disclosure:
Dr. Han has nothing to disclose.

Acquired Diseases of Muscle

Start Time

Pub.

Title

Presenter

11:30 AM

014

Dermatomyositis after Intralesional Immunotherapy for Warts

Disclosure:
Dr. Anderson has nothing to disclose.

Epilepsy: Antiseizure Medications II

Start Time

Pub.

Title

Presenter

11:30 AM

014

First Canadian experience of brivaracetam in a highly difficult to treat epilepsy population: a two-center clinical study

Disclosure:
Dr. Lafortune has nothing to disclose.

The Power of Case Reporting in Neuro-Oncology II

Start Time

Pub.

Title

Presenter

11:30 AM

014

Chemotherapy in Hemangioblastomatosis: A Case Report with Mutational Profiling and Literature Review

Disclosure:
Dr. Zhang has nothing to disclose.

Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support

Start Time

Pub.

Title

Presenter

11:30 AM

014

The Role of Induced Hypertension and Hyperbaric Oxygen Therapy in Moyamoya Disease: A Case Report

Disclosure:
Dr. Pabst has nothing to disclose.

Atypical Parkinsonism

Start Time

Pub.

Title

Presenter

11:30 AM

015

Expression change of plasma microRNAs in multiple system atrophy and Parkinson’s disease.

Disclosure:
Dr. Uwatoko has nothing to disclose.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

015

Medical Cannabis for Chronic Migraine: A Retrospective Review

Disclosure:
Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen, Boston Biomedical, electroCore, Alder Biopharmaceuticals, Lilly. Dr. Mechtler has received research support from Dent Family Foundation.

Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I

Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support

Start Time

Pub.

Title

Presenter

11:30 AM

017

Neurological Complications of Left Ventricular Assist Device

Disclosure:
Dr. Bandaru has nothing to disclose.

Atypical Parkinsonism

Start Time

Pub.

Title

Presenter

11:30 AM

018

RT001 to treat neurodegeneration—Case Study: Improvement in a single patient with Late Onset Tay-Sachs Disease (LOTS)

Disclosure:
Dr. Milner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Retrotpe. Dr. Milner has received compensation for serving on the Board of Directors of Retrotope, Espero Biopharma, Renexxion. Dr. Milner holds stock and/or stock options in Retrotope, Espero Biopharma, Renexxion which sponsored research in which Dr. Milner was involved as an investigator. Dr. Milner holds stock and/or stock options in Retrotope, Espero Biopharma, Renexxion.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

018

Obesity is Associated with Increased Odds of Hospitalization Following Emergent Care for Pediatric Migraine

Disclosure:
Dr. Szperka has received research support from Pfizer.

Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I

Start Time

Pub.

Title

Presenter

11:30 AM

018

Serial-position effect as a biomarker in the diferential diagnosis of mild cognitive impairment. A multimodal biomarkers aproach.

Disclosure:
Dr. Calandri has nothing to disclose.

MS Clinical Assessments and Outcome Measures

Start Time

Pub.

Title

Presenter

11:30 AM

018

The Impact of Cognitive Testing on Disability Measurement during the Follow-up of People with Multiple Sclerosis

A Futility Trial of Sirolimus in Multiple System Atrophy: Protocol, Recruitment and Preliminary Adverse Event Profile

Disclosure:
Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and Biogen. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.

Migraine I

Start Time

Pub.

Title

Presenter

11:30 AM

019

Visual discomfort in migraine is evoked by both melanopsin and cone directed stimulation

Tolerability and Effectiveness of Adjunctive Lacosamide in Patients with Cerebrovascular Epilepsy Etiology: Exploratory Post-hoc Analysis of A Non-interventional Trial

Disclosure:
Dr. Brandt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Desitin, Idorsia, Eisai. Dr. Brandt has received research support from UCB Pharma.

Interface of Sleep and Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

021

Witnessed Apneas During Sleep are Associated with Elevated Tau-PET Signal in the Entorhinal Cortex in Cognitively Unimpaired Elderly

Disclosure:
Dr. Carvalho has nothing to disclose.

Neurocritical Care: Case Reports

Start Time

Pub.

Title

Presenter

11:30 AM

021

A Case of Spinal Cord Edema with Cord Compression Due to Systemic Lupus Erythematosus and Osmotic Shifts, Treated with Hypertonic Saline.

Disclosure:
Dr. Cahan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epic.

Disclosure:
Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Biogen Idec, Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Roche, Celgene, Actelion, NMSS and MSIF.

Disclosure:
Dr. Elkind has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Vascular Dynamics, Merck/Organon, Auxilium, LivaNovaand. Dr. Elkind has received research support from BMS-Pfizer Alliance, Roche.

Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders

Disclosure:
Dr. Carroll has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd.

Neuro Trauma and Sports Neurology II

Start Time

Pub.

Title

Presenter

11:30 AM

027

Medical Cannabis in the Treatment of Post-Traumatic Concussion

Disclosure:
Dr. McVige has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Promius, Avanir, Gammacore, Depomed, Eli Lilly, Oxtellar, and Teva Pharmaceuticals. Dr. McVige has received research support from Dent Family Foundation.

Disclosure:
Dr. Shetty has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GE/NFL Medical Advisory Board. Dr. Shetty has received research support from General Electric, National Football League, Chembio/Perseus, ElMindA and Teva Pharmaceuticals.

Novel Biomarkers

Start Time

Pub.

Title

Presenter

11:30 AM

029

Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-risk Individuals: A Retrospective Cohort Analysis

Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting from Adamas, Celgene, Convelo, EMD Serono, Novartis, and PendoPharm; speaking for Mylan. Dr. Cohen has received personal compensation in an editorial capacity for Co-Editor of Multiple Sclerosis Journal – Experimental, Translational and Clinical.

Disclosure:
Dr. van Wamelen has received research support from Britannia Pharmaceuticals.

Neuro Trauma and Sports Neurology II

Start Time

Pub.

Title

Presenter

11:30 AM

033

Ground Reaction Force Patterns in the Golf Swing-Role in Injury Prevention and Performance

Disclosure:
Dr. Giombetti has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

033

Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial

Disclosure:
Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for serving as consultant or speaker from from Actelion, Biogen, EMD Serono, Genentech, Novartis, and Teva. Dr. Fox has received research support from Biogen (clinical trial contracts) and Novartis (research study support)..

Disclosure:
Dr. Gibbons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck Inc.. Dr. Gibbons has received personal compensation in an editorial capacity for Associate Editor for Autonomic Neuroscience: Basic and Clinical. Dr. Gibbons holds stock and/or stock options in Cutaneous NeuroDiagnostics. Dr. Gibbons has received research support from Grifols Inc..

Epilepsy: Diagnosis and Clinical Care II

Start Time

Pub.

Title

Presenter

11:30 AM

033

The Effect of Completing a Neurology Clerkship on Diagnostic Accuracy of Paroxysmal Spells

Disclosure:
Dr. Hanrahan has nothing to disclose.

Narcolepsy and Hypersomnolence

Start Time

Pub.

Title

Presenter

11:30 AM

033

Defining Disrupted Nighttime Sleep (DNS) in Pediatric Narcolepsy

Disclosure:
Dr. Maski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals, Inc and Harmony Biosciences, Inc. Dr. Maski has received royalty, license fees, or contractual rights payments from UptoDate, Inc. Dr. Maski holds stock and/or stock options in Sanofi/Genzyme, Inc. Dr. Maski has received research support from Jazz Pharmaceuticals, Inc.

Parkinson's Disease Therapeutics II

Start Time

Pub.

Title

Presenter

11:30 AM

033

Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's Disease: Results from a pooled meta-analysis

Disclosure:
Dr. Standaert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serina Therapeutics, Abbvie Inc., the Michael J. Fox Foundation for Parkinson Research, The International Parkinson Disease and Movement Disorder Society, The Parkinson Foundation, the National Institutes of Health, Oregon Health Sciences University, Voyager Therapeutics, Blue Rock Therapeutics, Clintrex LLC, Revivo Therapeutics, Sanofi-Adventis Research and Development, and US Department of Justice. Dr. Standaert has received license feed payments, royalties, or contractual rights from McGraw Hill, Inc. Dr. Standaert has received research support from Abbvie, Inc., Avid Radiopharmaceuticals, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Bachmann-Strauss Dystonia; Parkinson Foundation, and NIH grants.

Disclosure:
Dr. Steinman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene, Merck, Coherus, Atreca. Dr. Steinman has received compensation for serving on the Board of Directors of Atreca, Tolerion. Dr. Steinman has received royalty, license fees, or contractual rights payments from Tolerion. Dr. Steinman has received research support from Coherus, Celgene.

Disclosure:
Dr. Grebenciucova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Multiple Sclerosis Association of America, Presence Health, and Tenet Healthcare Corporation.

Narcolepsy and Hypersomnolence

Start Time

Pub.

Title

Presenter

11:30 AM

036

Burden of Narcolepsy: A Survey of Patients and Physicians

Disclosure:
Dr. Thorpy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Balance Therapeutics, Harmony Biosciences, LLC, Jazz Pharmaceuticals, Merck & Co. Dr. Thorpy has received research support from Balance Therapeutics, Harmony Biosciences, LLC, and Jazz Pharmaceuticals.

Parkinson's Disease Therapeutics II

Start Time

Pub.

Title

Presenter

11:30 AM

036

Safety and Efficacy of Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease in a Four-Week Double-blind, Placebo-controlled Randomized Crossover Study

Disclosure:
Dr. Videnovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Acadia, Jazz and Wilsons Therapeutics.

Disclosure:
Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.

Screening and Treatment for Osteoporosis after Stroke: Results from the Ontario Stroke Registry

Disclosure:
Dr. Kapoor has nothing to disclose.

Genetic Neuropathies

Start Time

Pub.

Title

Presenter

11:30 AM

037

A Giant Axonal Neuropathy (GAN)-like syndrome due to a mutation in Microtubule Associated Protein 1B (MAP1B): a new syndrome.

Disclosure:
Dr. Cupler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, and Novartis.

Narcolepsy and Hypersomnolence

Start Time

Pub.

Title

Presenter

11:30 AM

037

Misdiagnoses and Comorbidities among Participants in the Nexus Narcolepsy Registry

Disclosure:
Dr. Ohayon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Ohayon has received research support from Takeda.

Disclosure:
Dr. Kushlaf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Alexion, PTC therapeutics, Catalyst pharmaceuticals.

Narcolepsy and Hypersomnolence

Start Time

Pub.

Title

Presenter

11:30 AM

038

Healthcare Cost and Utilization Before and After Diagnosis in Pediatric Patients With Newly Diagnosed Narcolepsy: A Claims-based Analysis

Disclosure:
Dr. Reiss Reddy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Partnership for Health Analytic Research LLC. Dr. Reiss Reddy has received research support from Partnership for Health Analytic Research LLC to conduct this research.

Parkinson's Disease Clinical Features and Clinical Care I

Start Time

Pub.

Title

Presenter

11:30 AM

038

Reducing Complications in Hospitalized Parkinson's Patients

Disclosure:
Dr. Aslam has nothing to disclose.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

A Longitudinal Study of Hypersomnolence in the US General Population and its Chronicity

Disclosure:
Dr. Ohayon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Ohayon has received research support from Takeda.

Parkinson's Disease Clinical Features and Clinical Care I

Start Time

Pub.

Title

Presenter

11:30 AM

039

The Association of Gut Microbiome Composition and Parkinson’s Disease in Patient Cohort of Central California

Disclosure:
Dr. Chou has nothing to disclose.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Disclosure:
Dr. Stevens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals and Inspire. Dr. Stevens has received research support from Garmin.

Parkinson's Disease Clinical Features and Clinical Care I

Start Time

Pub.

Title

Presenter

11:30 AM

042

The effect of race on accuracy of coding with ICD-10 code G20

Disclosure:
Dr. Patel has nothing to disclose.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Disclosure:
Dr. De Seze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Teva, Novartis, Roche, Chugai, and Alexion. Dr. De Seze has received research support from Sanofi.

Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study

Disclosure:
Dr. Sprenger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with The employer of Dr Sprenger received compensation for his serving on scientific advisory boards and/or speaking from Sanofi Genzyme, Novartis, Actelion, Merck, Teva, Eli Lilly..

The Relationship Between Changes in Orthostatic Blood Pressure and Symptoms in Patients with Orthostatic Hypotension

Disclosure:
Dr. Freeman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abide, Applied Therapeutics, Astellas, Aptinyx, Biogen, Biohaven, Lundbeck, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray and Theravance. Dr. Freeman has received personal compensation in an editorial capacity for Autonomic Neuroscience - Basic and Clinical. Dr. Freeman has received compensation for serving on the Board of Directors of NeuroBo. Dr. Freeman holds stock and/or stock options in NeuroBo.

Parkinson's Disease Clinical Features and Clinical Care I

Start Time

Pub.

Title

Presenter

11:30 AM

046

Trajectories of cognitive and functional decline in Parkinson’s disease

Disclosure:
Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Aptinyx, Sunovion, and Worldwide Med. Dr. Goldman has received research support from Michael J. Fox Foundation, Parkinson's Foundation, NIH, and CHDI.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Start Time

Pub.

Title

Presenter

11:30 AM

046

Hypercalcemic Encephalopathy As An Initial Manifestation Of Hyperthyroidism Due To Endemic Goiter In Mexican Highlands, And Simultaneous Primary Hyperparathyroidism, A Case Report.

Disclosure:
Dr. Presas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Presas has received research support from Novartis, Biogen, and Merck.

Disclosure:
Dr. Kymes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and CVS Health. Dr. Kymes holds stock and/or stock options in Lundbeck that is greater than $10,000 in value which sponsored research in which Dr. Kymes was involved as an investigator.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Start Time

Pub.

Title

Presenter

11:30 AM

048

Olfactory Hallucinations as a Unique Presentation of Anti-depressant Discontinuation Syndrome

Disclosure:
Dr. Varade has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

049

Effect of ibudilast on macular measures in progressive MS: OCT analysis from a phase II trial

Disclosure:
Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis, Roche. Dr. Bermel has received research support from Biogen, Genentech, Roche.

Postprandial Hypotension in Parkinson’s Disease and Multiple System Atrophy

Disclosure:
Dr. Peltier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring, Lundbeck Pharmaceutical Companies, and Alnylam.

Parkinson's Disease Clinical Features and Clinical Care I

Start Time

Pub.

Title

Presenter

11:30 AM

049

Infections leading to hospitalization or sepsis preceding clinically diagnosed a-synucleinopathies: a case-control study in Olmsted County, MN (1991-2010).

Disclosure:
Dr. Hasan has nothing to disclose.

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Medication adherence and discontinuation in a national cohort of Medicare beneficiaries with Advanced Parkinson’s Disease

Disclosure:
Dr. Dahodwala has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia. Dr. Dahodwala has received research support from AbbVie, Roche, Ely Lilly and CalaHealth..

General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency

Cyclical Vomiting Associated with a Focal Lesion of the Area Postrema Successfully Managed with Medical Marijuana

Disclosure:
Dr. Hirsch has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

054

Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis

Disclosure:
Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

054

Evaluation of A Rapid Outpatient Stroke Clinic for TIA and Minor Stroke Patients in the Emergency Department

Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received =4 Courses

Disclosure:
Dr. Berkovich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva. Dr. Berkovich has received research support from Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

055

A Comparison of the Evaluation and Treatment of Transient Ischemic Attack in a Comprehensive Stroke Center and Four Acute Stroke Ready Hospitals

Does Lamotrigine Work for Migraine-Associated Vertigo Better than Topiramate?

Disclosure:
Dr. Jaffri has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

056

Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)

Disclosure:
Dr. Smoot has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi Genzyme, Genentech, EMD Serono, Novartis Pharmaceuticals, and Teva. Dr. Smoot has received research support from Biogen and Genentech.

Disclosure:
Dr. Shamim has received research support from Kaiser Permanente MidAtlantic Permanente Medical Group.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

057

Real-World Effectiveness of Alemtuzumab in Relapsing-Remitting MS Patients in Germany: Interim Results of the TREAT-MS Study

Disclosure:
Dr. Akgün has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, and Roche.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

057

The Existential Problem of Thrombolysis Aborted Stroke: A Case Presentation and Systematic Review

Disclosure:
Dr. Bush has nothing to disclose.

Autonomic Dysfunction: POTS and Peripheral Nerve

Start Time

Pub.

Title

Presenter

11:30 AM

057

Correlating Pathologic and Physiologic Measures in Ross Syndrome

Disclosure:
Dr. Loavenbruck has nothing to disclose.

General Neurology: Neurotherapeutics, Treatments, and Clinical Trials

Start Time

Pub.

Title

Presenter

11:30 AM

057

Effect of L-methylfolate on Depressive Symptoms in Patients with MTHFR Mutations

Disclosure:
Dr. Rainka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Postgraduate Healthcare Education, LLC, and Biogen. Dr. Rainka has received research support from Alexa, Acadia, ASHP, Dent Family Foundation.

Disclosure:
Dr. Singer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received consulting and/or speaking fees from AbbVie, Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme, and Teva. Dr. Singer has received research support from Barry Singer has received research grant support from AbbVie, Alkermes, MedImmune, Novartis, Roche, and Sanofi Genzyme .

Fingolimod does not seem to alter autonomic modulation of bladder in patients with relapsing-remitting multiple sclerosis

Disclosure:
Dr. Hilz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Hilz has received personal compensation in an editorial capacity for Autonomic Neuroscience: Basic and Clinical. Dr. Hilz has received research support from Novartis Pharma GmbH.

General Neurology: Neurotherapeutics, Treatments, and Clinical Trials

Start Time

Pub.

Title

Presenter

11:30 AM

058

Efficacy of Tissue Plasminogen Activator (tPA) vs. Aspirin in Patients with a National Institute of Health Stroke Scale (NIHSS) Score Under 5

Disclosure:
Dr. Hameed has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

059

Real-World Experience with Ocrelizumab

Disclosure:
Dr. Moss has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Genzyme and Roche. Dr. Moss holds stock and For stock options in Pfizer.

Disclosure:
Dr. De Seze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Teva, Novartis, Roche, Chugai, and Alexion. Dr. De Seze has received research support from Sanofi.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

063

Treatment within the Get with the Guidelines (GWTG) target of less than 45 minutes for intravenous thrombolysis improves 90 day outcome

Effects of Dimethyl Fumarate on Brain Volume Change in Relapsing-remitting Multiple Sclerosis: a Pooled Analysis of the Phase 3 DEFINE and CONFIRM Studies

Disclosure:
Dr. Nakamura has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NeuroRx Research and Sanofi Genzyme. Dr. Nakamura has received royalty, license fees, or contractual rights payments from license fee from Biogen Idec. Dr. Nakamura has received research support from Biogen Idec, Sanofi Genzyme, and Novartis.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

064

No Difference in Door-to-Needle Times by Choice of Antihypertensive Agent Prior to Thrombolysis: A Single Center Experience

Disclosure:
Dr. Carrera has nothing to disclose.

Autonomic Manifestations of Disease

Start Time

Pub.

Title

Presenter

11:30 AM

064

Autonomic manifestations before and after renal denervation.

Disclosure:
Dr. Gonzalez Duarte has nothing to disclose.

General Neurology: Advances in Quality of Care and Wellness

Start Time

Pub.

Title

Presenter

11:30 AM

064

The Functionality, Evidence and Privacy Issues around Smartphone Apps for the Top Neuropsychiatric Conditions: A Comprehensive Study

Disclosure:
Dr. Gopal has nothing to disclose.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

065

Discontinuation and Comparative Effectiveness of Dimethyl Fumarate and Fingolimod in Two Large Academic Medical Centers at 36-month Follow-Up

Disclosure:
Dr. Hersh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, Genentech, Genzyme, and EMD Serono. Dr. Hersh has received research support from Biogen Idec and Genentech.

Disclosure:
Dr. Scott has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi Genzyme, Novartis Pharmaceuticals, and Genentech. Dr. Scott has received research support from Biogen and Genentech.

Emergency Evaluation and Thrombolysis

Start Time

Pub.

Title

Presenter

11:30 AM

068

Louisiana’s Level III Stroke Center Performance Improvement Progress

Disclosure:
Dr. Martin-Schild has nothing to disclose.

Child Neurology: Neuromuscular Disease: Birth to Adulthood I

Start Time

Pub.

Title

Presenter

11:30 AM

068

White matter lesions detected by MRI in neonates and children with Congenital Myotonic Dystrophy

The Patient Odyssey to Confirmed Acute Hepatic Porphyria Diagnosis: Neurological Symptoms and Use of Drugs Known to Provoke Porphyria Attacks Prior to Diagnosis

Disclosure:
Dr. Pedro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals, Shire, and Sanofi Genzyme. Dr. Pedro has received research support from Shire, Sanofi Genzyme, Horizon Pharma, and Amicus Therapeutics.

Development of an AAV-based microRNA Gene Therapy for Treating Spinocerebellar Ataxia Type 3

Melvin EversDisclosure:
Dr. Evers has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with uniQure. Dr. Evers has received compensation for serving on the Board of Directors of uniQure. Dr. Evers holds stock and/or stock options in uniQure, Inc. which sponsored research in which Dr. Evers was involved as an investigator. Dr. Evers has received research support from uniQure, Inc..

Disclosure:
Dr. Bertolotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck, Novartis, Roche, Sanofi, and Teva.

General Neurology: Advances in Quality of Care and Wellness

Start Time

Pub.

Title

Presenter

11:30 AM

073

Positive Signs in Organic Neurological Diseases.

Disclosure:
Dr. Aboud has nothing to disclose.

Start Time

Pub.

Title

Presenter

074

STARS: Results from a safety and efficacy study of OV101 (gaboxadol) in adults and adolescents with Angelman syndrome

Lynne BirdDisclosure:
Dr. Bird has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Maximus Federal Services, Inventiv Health, FDNA, and Bionest Consulting. Dr. Bird has received personal compensation in an editorial capacity for Guest Editor for American Journal of Medical Genetics. Dr. Bird has received research support from Ovid Therapeutics.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

074

Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine

Disclosure:
Dr. Boster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Sanofi-Genzyme, Genetech, Teva, Medtronic. Dr. Boster has received research support from Biogen Idec, Novartis, Genetech, Actellion, and Sanofi-Genzyme.

Richard LiptonDisclosure:
Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven, which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation, the National Headache Foundation, and Amgen.

MS Clinical Trials and Therapeutic Research

Start Time

Pub.

Title

Presenter

11:30 AM

075

Effectiveness and Safety of Fingolimod in Patients Switching from Dimethy Fumarate, Teriflunomide, and Daclizumab in Daily Clinical Routine: Interim Results from PANGAEA 2.0

Serum Anti-JCV Antibody Status in Western Australian Patients With Multiple Sclerosis

Disclosure:
Dr. Pedrini has nothing to disclose.

General Neurology: Advances in Quality of Care and Wellness

Start Time

Pub.

Title

Presenter

11:30 AM

076

Demographic and Hemodynamic Characteristics of a large Cohort of Patients with Transient Global Amnesia (TGA)

Disclosure:
Dr. Werner has nothing to disclose.

Start Time

Pub.

Title

Presenter

077

Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS

Timothy MillerDisclosure:
Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Cytokinetics. Dr. Miller has received royalty, license fees, or contractual rights payments from C2N and Ionis Pharmaceuticals. Dr. Miller has received research support from Biogen, Ionis, Orion, and Amylyx.

General Neurology: Advances in Quality of Care and Wellness

Start Time

Pub.

Title

Presenter

11:30 AM

077

Quantifying the burden of unfilled clinic appointment slots created by late-notice cancellations

Sean PittockDisclosure:
Dr Pittock has provided consultation to Alexion Pharmaceutical and MedImmune but has received no personal fees or compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Pittock receives research support from Alexion Pharmaceuticals, Medimmune, and Grifols.

Disclosure:
Dr. Gaitan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Argentina, Biogen Argentina, and Merck Argentina. Dr. Gaitan has received research support from Novartis Argentina.

General Neurology: Advances in Quality of Care and Wellness

Start Time

Pub.

Title

Presenter

11:30 AM

079

Art Therapy in the Management of Neurology Wellness and Burnout- A Pilot Study

Disclosure:
Dr. Kappos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products. . Dr. Kappos has received research support from The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations.

Disclosure:
Dr. Giles has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Genzyme Corporation, and Biogen Idec.

11:30 AM

082

Sustained improvement in clinical and MRI outcomes in Newly Diagnosed relapsing-remitting multiple sclerosis (RRMS) patients treated for up to 4 years with peginterferon beta-1a: subgroup analysis of ADVANCE/ATTAIN

Disclosure:
Dr. Newsome has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genentech, medDay Pharmaceuticals, and Gerson Lehrman Group.. Dr. Newsome has received research support from Biogen, Genentech, Department of Defense, the National MS Society, and Patient-Centered Outcomes Research Institute.

11:30 AM

083

Biotin in Progressive Multipe Sclerosis in real-life

Disclosure:
Dr. Moreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme. Dr. Moreau has received research support from Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme.

Disclosure:
Dr. Gaughan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Novartis, Abbvie, Biogen. Dr. Gaughan has received research support from Roche via Newman Fellowship, University College Dublin.

Disclosure:
Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Biogen, Novartis, Teva Neuroscience and Roche Diagnostics Corporation. He has also received consultancy fees for advisory board meetings for Merck-Serono, Genzyme-Sanofi, Synthon BV, and Physicians’ Summit and several medical education meetings. Dr. Giovannoni has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders (Elsevier). Dr. Giovannoni has received research support from Takeda Pharmaceutical Company.

Disclosure:
Dr. Kappos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products. . Dr. Kappos has received research support from The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations.

Disclosure:
Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Biogen, Novartis, Teva Neuroscience and Roche Diagnostics Corporation. He has also received consultancy fees for advisory board meetings for Merck-Serono, Genzyme-Sanofi, Synthon BV, and Physicians’ Summit and several medical education meetings. Dr. Giovannoni has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders (Elsevier). Dr. Giovannoni has received research support from Takeda Pharmaceutical Company.

11:30 AM

101

The effect of cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLE-MS study

Disclosure:
Dr. Nicholas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Medtronic, Novartis Pharmaceuticals, Sanofi Genzyme, and Teva. Dr. Nicholas has received research support from Biogen, Novartis Pharmaceuticals, and Sanofi.

11:30 AM

103

Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis.